INBRX-106 with Keytruda (pembrolizumab)
- Indication
- Locally advanced unresectable or metastatic head and neck squamous cell carcinoma (HNSCC)
- Stage
- phase3
- Event
- Conference Presentation
- Details
September 4, 2026: Inhibrx Biosciences, Inc. (NASDAQ: INBX) announced a live webcast for September 8, 2026 at 5:00 a.m. PT to provide primary endpoint results from the randomized, controlled Phase 2 portion of the HexAgon study of INBRX-106 in first-line head and neck squamous cell carcinoma.
INBRX-106, a hexavalent OX40 agonist, is being evaluated in combination with pembrolizumab versus pembrolizumab monotherapy in treatment-naïve, PD-L1-positive (CPS ≥20) metastatic or unresectable recurrent HNSCC patients. The announcement identifies the upcoming catalyst as release of the Phase 2 primary endpoint results; no efficacy or safety outcomes are disclosed in this press release.
The company said the webcast will include a slide presentation of the data, which will also be incorporated into its investor deck, and the replay will remain available for 60 days.
- Source
- View catalyst source ↗